Grifols

We are pleased to announce that GigaGen, a Grifols company, has received FDA approval to begin a Phase 1 trial to evaluate its recombinant polyclonal drug to treat and potentially clear hepatitis B virus infection (HBV). The therapeutic, containing more than 1,000 fully human recombinant anti-HBV antibodies that reproduce the human body’s natural immune response, marks a significant milestone for Grifols as part of its commitment to develop transformative antibody drugs for infectious diseases. For more information, see the press release 👉 https://lnkd.in/dseNnWzM #biotechnology #antibodies #WeAreInnovation 

We are proud to announce that the 2024 GATRA Award winner is Dr. Luis Muñoz Becerra, Senior Research Investigator Group Leader at FAU Erlangen-Nürnberg for his research project titled ¨Inhibition of serine proteases in tumor associated neutrophil extracellular traps (taNETs) by antithrombin¨. Founded in 2015, the GATRA Program is an annual international award to foster a scientific network and also the knowledge in the use of Antithrombin as a therapeutic product. More information here 👉 https://bit.ly/3LAJ2pa #hematology #clinicalresearch #GrifolsScientificAwards

Today we released our financial results for the second quarter of 2024, in which we accelerated our performance and reaffirmed guidance for the full year. We delivered revenues of EUR 1.8 billion (a 9% increase), an adjusted EBITDA of EUR 441 million (24.1%), positive free cash flow of EUR 57 million and a significant reduction of our leverage ratio, to 5.5x. We are focused on building on this strong performance, implementing our Cash Flow Improvement Plan, further reducing debt and executing operations effectively. Learn more here 👉 http://spr.ly/6048cvmrE

We are very pleased that the U.S. FDA has approved an expanded label for XEMBIFY® to include treatment-naïve patients with primary humoral immunodeficiencies. It is the first and only 20% subcutaneous immunoglobulin (SCIg) that enables patients to go straight to SCIg without initial intravenous Ig therapy. The extended label, which also includes biweekly dosing, provides patients with added flexibility and convenience. Increasing adoption of XEMBIFY is part of Grifols’ broader Ig business strategy focused on treating immunodeficiencies, which represent more than half of the total Ig market. For more information, see the press release. 👉 http://spr.ly/6048cWzfj #Immunology #WeAreInnovation

❤️ Voluntary plasma donations make the production of our medicines possible. With the largest network of donor centers in the world, we ensure that donations take place in highly controlled and secure environments. Choosing to make a plasma donation is a vital and very rewarding experience, but it’s also a commitment. 👉 We would like to show you the plasma donation process in one of our centers in the United States, one of the countries where donors receive a monetary compensation for their valuable time and effort. #GrifolsPlasma #PlasmaSourceOfLife

We are glad to announce that the 2024 Award for Scientific Progress in Immunodeficiency Research (ASPIRE) winner is Dr. Quentin Riller from Institut Imagine Necker Hospital, Paris (France) for his research project entitled “Enteric virus associated hepatitis in patients with a defective antibody response (EVAHDAR) as a new immunopathological condition”.    The ASPIRE award is a significant initiative by Grifols that aims to foster innovative clinical research in the field of primary and secondary immunodeficiency diseases. It offers a grant to support young scientists and clinicians who propose projects that can improve the awareness, diagnosis, and management of immunodeficiency diseases, as well as develop novel concepts in immunoglobulin therapy.     For more information 👉 https://bit.ly/3Wb6fmH #research #Immunology #GrifolsScientificAwards 

For almost a decade, we’ve partnered with Habitat for Humanity International - donating our time, energy and funds to help build homes, communities and hope. Together, we are committed to making housing affordability a reality and ensuring that families around the world have a place to call home. This collaboration goes beyond construction. It's about creating a foundation for stronger, more resilient communities. It’s about people coming home – a great journey that we started in 2015 to support the surrounding Emeryville communities. #CommunityBuilding #CorporateResponsibility #GrifolsSocialInitiatives

✨ 1972 marked a milestone in the history of Grifols when we inaugurated our first large industrial plant in Parets del Vallès, near Barcelona. Production was moved from the first site in Barcelona to these new facilities enabling the company to take its manufacturing of pharmaceutical products to an industrial scale. In the 1970s, Grifols was mainly dedicated to the production of intravenous solutions, as well as diagnostic instrumentation and reagents, followed by the production of plasma-derived medicines. It was not until the 1990s, however, that plasma-derived medicines began to lead in terms of production volume and sales. The new millennium brought with it a paradigm shift in the way we produce and build our factories that have subsequently been transferred to the rest of our plants around the world. Learn more on our business history 👉 http://spr.ly/60429WVcj

On the 20th anniversary of the ALTA Awards, we are proud to announce that the 2024 ALTA Award winners are: 🔹 Dr. Tessa Schneeberger , from Philipps-University of Marburg/Schön Klinik Berchtesgadener Land (Germany) for her research on “Psychological disorders in COPD patients with AATD – prevalence and effects of psychotherapeutic intervention and its impact on quality of life” 🔹 Dr. Benoit Allard from Université de La Réunion (France), for his project “Novel therapeutic strategy with alpha-1-antitrypsin-enriched nanoparticles”. Founded in 2004 the ALTA Awards support annually independent research by young investigators to shape the future of AATD therapy. At Grifols we are committed to pushing the boundaries of scientific knowledge to improve people’s health. For more information 👉 http://spr.ly/6043iOSST #pulmonology #geneticcopd #GrifolsScientificAwards

When someone invests their time in helping others, they deserve the best experience and care. We are thrilled to announce a first step in our journey to enhance donor experience through digital transformation in our more than 300 centers in the U.S. Through our new website, chatbot service and DonorHub™ 3.0 donor app, we are streamlining the donation process and providing our valued donors with a more convenient and engaging experience. We're not just updating our donor digital assets; we're improving the way we connect with donors. Thanks to all our team members involved! See our new website and learn more about donating plasma 👉 http://spr.ly/6042iulIM #PlasmaSourceOfLife